m+Medelevator.RU
← Поиск публикаций
Scientific reports · 2026

Intravascular behavior of cutaneous polynucleotide injectables following intra-arterial exposure.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Boonpethkaew Suphagan, Suwanchinda Atchima, Yingmema Werayut, Thanasarnaksorn Wilai

Аннотация

Polynucleotide (PN) injectables are increasingly used in aesthetic medicine, making a clear understanding of their intravascular behavior essential. We conducted a controlled animal study using a rabbit central ear artery model to evaluate the cutaneous consequences of intra-arterial PN injection, comparing formulations with differing viscosities (Rejuran S, Rejuran HB Plus, and Conjuran) with normal saline and cross-linked hyaluronic acid (HA). Arterial flow dynamics, the presence of persistent emboli at 24 h, clinical ischemia, and histopathologic change were assessed. Among the three formulations, Conjuran (higher-viscosity PN) demonstrated the highest frequency of transient arterial occlusion, followed by Rejuran HB Plus (low-viscosity PN combined with non-cross-linked HA), whereas Rejuran S (high-viscosity PN) exhibited the lowest incidence. Importantly, all PN-related flow disturbances were transient, with no visible transparent emboli detected at 24 h and no clinical ischemia or histopathologic evidence of necrosis, vasculitis, or vasculopathy observed on day 7. In contrast, cross-linked HA resulted in persistent intravascular emboli and extensive tissue necrosis. In conclusion, this study demonstrated transient flow disturbance without persistent embolization or ischemia following intra-arterial exposure to PN in this rabbit ear artery model. Further investigation is warranted to define the underlying mechanisms and to characterize microvascular effects and embolic burden.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты